ArticleVeterinary research communications2026
"Expression of a recombinant chimeric capsid-nucleocapsid protein from bovine leukemia virus genotype 1 for the diagnosis of enzootic bovine leukosis".
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bovine Leukemia Virus (BLV) is the causative agent of enzootic bovine leukosis (EBL), a neoplastic disease responsible for significant economic losses in the cattle industry. While diagnostic tests primarily target the capsid (p24) and envelope (gp51) proteins, the immunodiagnostic potential of the nucleocapsid protein (p12) remains underexplored. This study aimed to express a recombinant chimeric capsid-nucleocapsid protein (p24-p12) from BLV genotype 1 and evaluate its diagnostic performance. Following in silico epitope prediction, an 851 bp fragment of the gag gene encoding the chimeric protein (RCP24-12) was cloned, expressed in E. coli, and used to develop an indirect ELISA. The assay was used to test 680 plasma samples from Holstein Friesian cattle and compared to a commercial gp51-based ELISA. Discordant results were resolved by Western blot (WB) using RCP24-12 as antigen. The RCP24-12 ELISA detected antibodies in samples negative by the commercial test. Using a composite reference standard (commercial ELISA + WB), the in-house assay demonstrated a sensitivity of 88.8% and a specificity of 79.2%. These findings indicate that the recombinant chimeric protein p24-p12 is a promising antigen for the serological diagnosis of BLV genotype 1 infection, offering improved detection capability over a single-protein (gp51) antigen.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.